Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Nordic Nanovector
Nordic Nanovector
Activities:
Research & Development
X
LinkedIn
Trending Articles
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Overcoming CMC challenges in cell and gene therapy: part II
Certara’s Dr Hien Anh Bruno, Associate Director, Chemistry, Manufacturing and Controls (CMC), and Dr Deven Shah, CMC Lead, propose mitigation strategies to address the CMC...
SNIPR Biome receives funding to progress CRISPR medicine SNIPR001 into clinical trials
Phase 1b/2a trial will evaluate SNIPR001 for the prevention of E.coli infections in patients undergoing hematopoietic stem cell transplantation
Kindeva Drug Delivery appoints Denis Johnson as Chief Operating Officer
Denis will be responsible for optimising global operations for the company
SeaBeLife awarded over €1.5 million in i-Nov innovation competition
Funding for company’s SeaBeEYE project will be used to develop a new therapeutic approach for geographic atrophy, a form of age-related macular degeneration
Upcoming event
Cleanroom Conference UK
22–23 May 2024 | Exhibition | Birmingham, UK
See all
Related Content
Finance
Nordic Nanovector to explore strategic options
Nordic Nanovector announces that its Board of Directors has appointed Carnegie Investment Bank to explore strategic options available to the company
Finance
Nordic Nanovector appoints Peter Braun CEO
In addition to his experience at Roche, Braun has also held roles at an artificial intelligence (AI)-driven life sciences start-up and as strategy consultant to emerging healthcare companies
Regulatory
Nordic Nanovector appoints Dr Reza Safaei as head of Medical Affairs
Nordic Nanovector appoints Lisa Rojkjaer, MD as Chief Medical Officer
Nordic Nanovector ASA (OSE: NANO) is pleased to announce that Lisa Rojkjaer, MD has joined the company today as Chief Medical Officer (CMO) and as a member of the Executive Management Team.
Ingredients
Nordic Nanovector and Heidelberg Pharma collaborate to develop novel ADCs targeting leukaemias
Leukaemias are orphan diseases with a significant unmet medical need, applicable indications representing a growing market worth more than $5 billion by 2020
Ingredients
Nordic Nanovector and LegoChem Biosciences collaborate to develop novel antibody-drug conjugates (ADCs) targeting leukaemias
Leukemias are orphan diseases with a significant unmet medical need, representing a growing market estimated to be worth more than $5 billion by 2024
Regulatory
Betalutin publications highlight benefits of predosing regimen
Lilotomab predosing of NHL patients before Betalutin therapy lowers haematological toxicity with no reduction in the tumour absorbed radiation dose
Subscribe now